Ventana Biotech Inc
PINK SHEETS : VNTA

Ventana Biotech Inc

October 26, 2009 17:35 ET

Ventana Pre-liminary Offer for Its IP

NEW YORK, NEW YORK--(Marketwire - Oct. 26, 2009) - Ventana Biotech Inc. ("Ventana") (PINK SHEETS:VNTA), a biotechnology company developing an appetite-suppressing and stress reducing chewing gum, today announced it has been contacted by a US company for the acquisition of its intellectual property.

Ventana was approached by a US based company early in October and has entered into early negotiations regarding the sale of Ventana's intellectual property. Management wishes to emphasis that the negotiations are in the early stages and it remains uncertain as to whether the parties will be able to arrive at a definitive mutual agreement. However, management deemed it prudent and in the best interests of its shareholders to inform the shareholders of these negotiations.

Ventana expects to be able to make a further announcement regarding the status of the negotiations within the next two weeks as negotiations are progressing.

About Ventana Biotech Inc

Ventana is positioning itself as the leading bioscience company in the development and commercial licensure of novel therapeutic medical chewing gum drug treatment. The company leverages cutting-edge research collaborations to achieve breakthroughs in innovative medical chewing gum treatments, and then licenses these patent pending product candidates to Big Pharmaceutical and Biotechnology companies.

FORWARD-LOOKING STATEMENTS:

Statements about Ventana's future expectations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as the term is defined in the Private Litigation Reform Act of 1995. Ventana's actual results could differ materially from expected results. Ventana does not undertake any obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. Should events occur which materially affect any comments made within this objective; Ventana will appropriately inform the public.

For more information about Ventana Biotech Inc please contact investor@ventanabiotech.com

Contact Information

  • Ventana Biotech Inc
    Janne Christensen
    CEO
    + 41-44-732-60-59